Jaguar Health, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; financial statements are unaudited. Jaguar is a commercial-stage pharmaceutical company focused on plant-derived human and animal health products. Its main commercial product is Mytesi (crofelemer); its pipeline includes crofelemer indications and NP-300.
Financial results and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Net product revenue | $2.351 million | $1.972 million; up 19.2% |
| Cost of product revenue / gross margin | $0.430 million / approximately 81.7% | $0.345 million / approximately 82.5% |
| Operating expenses | $10.566 million | $11.817 million; down 10.6% |
| Operating loss | $8.215 million | $9.845 million |
| Net loss | $9.368 million | $12.397 million |
| Net loss attributable to common stockholders / per share | $9.226 million / $0.06 | $12.202 million / $2.39 |
| Cash from operating activities | $(7.047) million | $(9.945) million |
| Cash from financing activities | $12.268 million | $18.811 million |
| Cash at period end | $11.671 million | $14.367 million |
At March 31, 2024, total assets were $55.389 million, current assets $33.714 million, current liabilities $17.814 million, total liabilities $41.086 million, and stockholders’ equity $11.818 million. Notes payable, net, totaled $32.113 million, including $10.394 million current. The accumulated deficit was $317.215 million. Product revenue was overwhelmingly Mytesi; two specialty-pharmacy customers generated 85% of quarterly revenue.
Material changes and financing
- Revenue increased, while operating expenses declined, primarily reflecting lower R&D, sales and marketing, and G&A spending. Cost of product revenue rose, and gross margin edged down.
- Interest expense declined to $0.611 million from $2.181 million, mainly following fair-value-option accounting for certain debt. This was partly offset by a $2.021 million fair-value loss on financial instruments, versus a $0.359 million loss a year earlier. A $1.245 million debt-extinguishment gain also benefited the quarter.
- The ATM offering generated $11.340 million net proceeds through issuance of approximately 130.9 million shares. The company also received approximately $2.0 million gross proceeds associated with an Eastern Europe crofelemer license and issued 16.7 million shares in that transaction. Subsequent to quarter-end, it raised $2.2 million net through additional ATM share sales through May 14.
- Debt exchanges and warrant conversions added substantial shares: among other transactions, PIPE warrants covering 7.535 million shares were exchanged for 18.838 million common shares. Voting common shares outstanding were 273.5 million at March 31 and 293.4 million at May 14.
Outlook, risks, and unusual items
- Going concern: Management states existing cash is not sufficient to fund its operating plan for one year from issuance of the statements; substantial doubt exists about the company’s ability to continue as a going concern. Jaguar expects further losses and negative operating cash flow and depends on additional financing, partnerships, licensing proceeds, or improved product cash flows. Funding may not be available on acceptable terms or in time.
- Royalty obligations: Certain royalty financings require minimum payments regardless of product sales. The filing identifies total minimum royalty payments of $27.0 million in 2026, a potential significant cash burden.
- Nasdaq listing: After a delisting determination related to the minimum bid-price requirement, the company obtained a hearing and an extension to regain compliance through August 13, 2024.
- Development and commercial plans: Enrollment in the pivotal OnTarget Phase 3 trial of crofelemer for prevention of cancer-therapy-related diarrhea was completed; the supplied filing text does not provide a clear trial outcome. Proof-of-concept data for a lyophilized product is expected by year-end 2024. Jaguar planned a Q3 2024 U.S. launch of licensed product Gelclair.
- Operating concentration: Mytesi accounts for substantially all revenue; two customers represented 85% of Q1 revenue. The company depends on two raw-material suppliers and one third-party finished-product manufacturer.
- The company reported no material current legal proceedings or material legal accruals. Management concluded disclosure controls and internal control over financial reporting were effective as of March 31, 2024.
Important facts for investors to verify
- Funding runway, financing availability and the company’s going-concern status, including the cash impact and timing of royalty minimums.
- Nasdaq bid-price compliance progress and any further actions required before the August 13, 2024 deadline.
- OnTarget trial results and timing, and the evidence and regulatory milestones needed for other pipeline programs and Gelclair commercialization.
- Revenue durability and customer concentration, as well as supply-chain alternatives for Mytesi.
- Share-count dilution, remaining ATM capacity, debt exchange terms, and the sensitivity of Level 3 fair-value debt estimates to unobservable assumptions.
- Cash-flow figures differ within the filing: the financial statements report operating cash use of $7.047 million and financing cash of $12.268 million, while the MD&A cash-flow summary reports $7.897 million and $13.118 million, respectively. The financial-statement figures reconcile to the reported $5.202 million net increase in cash; investors should confirm the discrepancy with the company or subsequent filings.